MARKET

XOMAP

XOMAP

XOMA Royalty Corporation
NASDAQ
26.48
+0.27
+1.03%
Opening 11:46 04/02 EDT
OPEN
27.30
PREV CLOSE
26.21
HIGH
27.30
LOW
26.41
VOLUME
4.28K
TURNOVER
--
52 WEEK HIGH
28.80
52 WEEK LOW
23.47
MARKET CAP
26.06M
P/E (TTM)
18.19
1D
5D
1M
3M
1Y
5Y
1D
2 Royalty Income Streams You Don't Have To Work For
Seeking Alpha · 2d ago
XOMA Royalty announces annual shareholder meeting via virtual webcast
Reuters · 2d ago
Weekly Report: what happened at XOMAP last week (0323-0327)?
Weekly Report · 3d ago
Weekly Report: what happened at XOMAP last week (0316-0320)?
Weekly Report · 03/23 09:53
XOMA Preferred Shares Series A declares $0.5391 dividend
Seeking Alpha · 03/18 20:41
XOMA Royalty declares USD 0.53906 Series A preferred dividend per share and USD 0.52344 Series B preferred dividend per depositary share
Reuters · 03/18 20:30
XOMA Royalty Declares Quarterly Preferred Stock Dividends
Barchart · 03/18 15:30
XOMA 2025 income, revenue jump on portfolio expansion, milestone payments
Reuters · 03/18 10:10
More
About XOMAP
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.

Webull offers XOMA Royalty Corp stock information, including NASDAQ: XOMAP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XOMAP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XOMAP stock methods without spending real money on the virtual paper trading platform.